GlassScriptPhysician profile
Yinghong Wang
NPI 1164699047
$10,827.01
in general payments reported to CMS, 2019-2025
17 companies · $3,841 in 2025
The $3,841 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2023: $389 · 2024: $4,764 · 2025: $3,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,350 · Food and Beverage: $2,392 · Travel and Lodging: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,350.00 |
| Food and Beverage | $2,391.89 |
| Travel and Lodging | $2,252.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $3,350.00 | 2024 | Cellex |
| Ferring Pharmaceuticals INC. | $2,114.98 | 2023-2025 | Rebyota |
| Exelixis INC. | $1,557.25 | 2019 | |
| Biontech Se | $1,000.00 | 2024 | |
| Abbvie INC. | $969.89 | 2025 | |
| 3-D Matrix, INC. | $490.44 | 2024-2025 | |
| Janssen Biotech, INC. | $249.49 | 2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $238.41 | 2023-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $145.00 | 2019 | |
| Beigene USA, INC. | $129.26 | 2023 | Brukinsa |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Astellas Pharma US INC | $124.98 | 2024 | Vyloy |
| Lilly USA, LLC | $121.82 | 2024 | Omvoh |
| Conmed Corporation | $83.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.36 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.33 | 2019 | |
| Pentax of America, INC. | $16.47 | 2023 | N/A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yinghong Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.